Mesenchymal stem cells elicits Anti-PD1 immunotherapy by targeted delivery of CX3CL1

• Váldodahkkit: Jize Liu (Dahkki), Xiaomin Ma (Dahkki), Chuxuan Liu (Dahkki), Yang Cheng (Dahkki), Bingjun Li (Dahkki), Wenjie Zhang (Dahkki), Runzhi Zeng (Dahkki), Qishuai Chen (Dahkki), Yun Zhang (Dahkki), Sanyuan Hu (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Frontiers Media S.A., 2023-02-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Anti-PD1/PDL1 monotherapy has failed to acquire sufficiently ideal results in most solid tumors. Mesenchymal stem cells (MSCs) have been reported to exert therapeutic effects on some tumors, but the functions of MSCs in colorectal cancer (CRC) need further research. In this study, we aimed to invest...